Results Update

January 2007
PharmaWatch: Biotechnology;Jan2007, Vol. 6 Issue 1, p7
Market Research Report
The article offers world news briefs related to drug development. Dynavax Technologies Corp. released the outcome of its clinical trials of hepatitis B virus vaccine Hepsilav. Cell Therapeutics Inc. terminated the Xyotax lung cancer trial because of its inefficiency in treating lung cancer. The synDNA vaccine of CytoGenix Inc. was proven to be an effective drug for HIV viruses.


Related Articles

  • ICAAC 2011.  // BioWorld Today;9/20/2011, Vol. 22 Issue 182, p7 

    The article focuses on the results presented by Dynavax Technologies Corp. at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) from a Phase III trial of the HBV-16 hepatitis B vaccine.

  • Dynavax's Heplisav Hits Endpoint in HBV Trial. Morrison, Trista // BioWorld Today;8/7/2008, Vol. 19 Issue 153, p1 

    The article reports that the Phase III trial of the Heplisav hepatitis B vaccine (HBV) has met its goal of inducing a non-inferior antibody response compared to the Engerix-B vaccine of GlaxoSmithkline. The entry notes that 95 percent of 1,819 patients developed HBV antibodies upon receiving a...

  • Dynavax Raises $44M for Phase III HBV Vaccine.  // Bioworld Week;4/19/2010, Vol. 18 Issue 16, p4 

    The article reports that the Berkeley, California-based Dynavax Technologies Corp. is raising 44 million dollars fund to support its development of the hepatitis B vaccine Heplisav.

  • Merck Paying $31M Up Front In Dynavax HBV Vaccine Deal. Osborne, Randall // BioWorld Today;11/2/2007, Vol. 18 Issue 214, p1 

    The article reports on the payment of $31.5 million by Merck & Co. Inc. to Dynavax Technologies Corp. to develop the Phase III hepatitis B virus vaccine Heplisav. This forms part of the $105 million in potential milestone payments plus royalties as the two firms look forward to filing for...

  • Heplisav Data Disappoint; Dynavax Stock Sinks 19%. Powers, Marie // BioWorld Today;7/21/2011, Vol. 22 Issue 140, p1 

    This article reports on the release of the Phase III trial of the investigational hepatitis B vaccine Heplisav by Dynavax Technologies Corp. in 2011. The trial compared the investigational vaccine to the hepatitis B vaccine Engerix-B from GlaxoSmithKline (GSK). Dynavax claimed that its vaccine...

  • Dynavax: limited potential for Heplisav despite promising data.  // PharmaWatch: Monthly Review;Jan2007, Vol. 6 Issue 1, p34 

    The article reports on the limited commercial potential of Dynavax Technologies Corp.'s hepatitis B vaccine called Heplisav despite the positive results of its clinical trial. The trial shows the vaccine's 100% seroprotection on 18 and 39 years old patients in two vaccination schedules. However,...

  • DYNAVAX INITIATES PHASE 3 TRIAL FOR HEPATITIS B VACCINE.  // Biotech Business;Aug2005, Vol. 18 Issue 8, p2 

    Reports on a clinical trial initiated by biopharmaceutical company Dynavax Technologies Corp. for its hepatitis B vaccine in 2005. Information on the vaccine; Number of seronegative adults to be involved in the trial; Background on Dynavax.

  • Dynavax Raises $44M to Push Phase III HBV Vaccine Heplisav. Morrison, Trista // BioWorld Today;4/14/2010, Vol. 21 Issue 71, p1 

    The article announces the plan of Dynavax Technologies Corp. to raise 44 million U.S. dollars. With this, the firm intends to make a public offering of stock and warrants. Proceeds will be used for the Phase III trials of its hepatitis B vaccine Heplisav and for its license application filing in...

  • EASL Roundup.  // BioWorld Today;4/28/2009, Vol. 20 Issue 80, p6 

    The article reveals the results of the Phase III PHAST clinical trial of Dynavax Technologies Corp. for its hepatitis B vaccine Heplisav. The clinical trial compares the company's vaccine with GlaxoSmithKline plc's marketed hepatitis B vaccine, Engerix-B. Information is also given on the stock...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics